From available case reports, compounding pharmacy data, and practitioner experience, the following have been observed: BPC-157 Reported Side Effects Nausea and gastrointestinal discomfort (especially with oral administration) Dizziness or light-headedness Flushing or warmth at injection sites Headache Fatigue or somnolence in some users TB-500 Reported Side Effects Injection site reactions (redness, mild pain, swelling) Transient fatigue or lethargy following administration Headache Possible flu-like symptoms in a minority of users Long-Term Risks: What We Don't Know This is arguably the most vital part of this guide
Supplementing with a bioavailable form is often necessary to significantly raise systemic levels
Antioxidants 9 , 111 (2020)
The ratio of GSH to GSSG is a key indicator of cellular oxidative stress, with a healthy cell maintaining a ratio greater than 100:1 [2][5]
Andrology 9 , 368375 (2021)
In April 2026, the FDA announced that its Pharmacy Compounding Advisory Committee (PCAC) will meet on July 23 and 24, 2026, to discuss several peptide-related bulk drug substances for possible inclusion on the 503A Bulks List